The Drive to Develop New Commercial Models

By all accounts, biopharma executives have a complex 2010 agenda, requiring that they work tirelessly to: Reconsider their basic business models while driving efficiencies in their in-line assets, with 75% of mature markets being undifferentiated (see box) by 2015 Improve […]

Read More